TCP and NTCP in preclinical and clinical research in Europe

Rays - International Journal of Radiological Sciences

Volumn 30, Issue 2, 2005, Pages 121-126

  Baumann, Michael ^a,b   Petersen, Cordula ^a   Krause, Mechthild ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Europe; Radiation Oncology; TCP NTCP Therapeutic window

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CONCEPT FORMATION; EUROPE; NORMAL TUMOR COMPLICATION PROBABILITY; PROCESS OPTIMIZATION; RADIOBIOLOGY; STATISTICAL MODEL; TUMOR CONTROL PROBABILITY;

ANIMALS; BIOMEDICAL RESEARCH; DOSE-RESPONSE RELATIONSHIP, RADIATION; EUROPE; HUMANS; NEOPLASMS; RADIATION INJURIES; RADIATION ONCOLOGY; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 27744439453     PISSN: 03907740     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. VERONESI U, CASCINELLI N, MARIANI L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-1232.
2. OVERGAARD M, JENSEN MB, OVERGAARD J et al. Postoperative radiotherapy in high-risk post-menopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-1648.
3. OVERGAARD M, HANSEN PS, OVERGAARD J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955.
4. SCHAAKE-KONING C, VAN DEN BOGAERT W, UALESIO O et al. Effects of concomitant cisplatin and radiotherapy on inoperable non- small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
5. BARTELINK H, ROELOFSEN F, ESCHWEGE F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15: 2040-2049.
6. SAUER R, BECKER H, HOHENBERGER W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
7. BUDACH V, STUSCHKE M, BUDACH W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23: 1125-1135.
8. BAUMANN M, BENTZEN SM, DOERR W, et al. The translational research chain: is it delivering the goods? Int J Radiat Oncol Biol Phys 2001; 49: 345-351.
9. HORIOT JC, LE FUR R, N'GUYEN T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992; 25: 231-241.
10. OVERGAAHD J, HANSEN HS, SPECHT L et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-940.
11. SAUNDERS M, DISCHE S, BARRETT A, HARVEY A, GIBSON D, PARMAR M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350: 161-165.
12. BAUMANN M, APPOLD S, ZIPS D, NESTLE U, PETERSEN C, HERRMANN T. Modified fractionation in the radical treatment of non-small cell lung cancer. Front Radiat Ther Oncol 2000; 34: 80-88.
13. NORDSMARK M, OVERGAARD M, OVERGAARD J. Pretreatment oxygen predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-39.
14. OVERGAARD J, HANSEN HS, OVERGAARD M et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-146.
15. KAANDERS JH, BUSSINK J, VAN DER KOGEL AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-737.
16. ROJAS A, CARL U, REGHEBI K. Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies. Int J Radiat Oncol Biol Phys 1990; 18: 547-553.
17. BAUMANN M, KRAUSE M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother. Oncol. 2004, 72: 257-266.
18. BAUMANN M, KRAUSE M, ZIPS D et al. Molecular targeting in radiotherapy of lung cancer. Lung Cancer 2004; 45 Suppl 2: S187-197.
19. DITTMANN KH, DIKOMEY E, MAYER C, RODEMANN HP. The Bowman-Birk protease inhibitor enhances clonogenic cell survival of ionizing radiation-treated nucleotide excision repair-competent cells but not of xeroderma pigmentosum cells. Int J Radiat Biol 2000; 76: 223-229.
20. BAUMANN M, HOLSCHER T, BEGG AC. Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiother Oncol 2003; 69: 121-125.
21. VAN 'T VEER LJ, DAI H, VAN DE VIJVER MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
22. SONKE JJ, ZIJP L, REMEIJER P, VAN HERK M. Respiratory correlated cone beam CT. Med Phys 2005; 32: 1176-1186.
23. SMITSMANS MH, WOLTHAUS JW, ARTIGNAN X et al. Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60: 623-635.
24. KUMAR S, BURKE K, NALDER C et al. Treatment accuracy of fractionated stereotactic radiotherapy. Radiother Oncol 2005; 74: 53-59.
25. BENTZEN SM. Diagnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6: 112-117.
26. HOLTHUSEN H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren Nutzanwendung zur Verhütung von Schäden. Strahlenther 1936; 57: 254-269.
27. BAUMANN M, BUDACH V, APPOLD S. Strahlentoleranz des menschlichen Rückmarks. Strahlenther Onkol 1994; 170: 131-139.
28. SCHULTHEISS TE, STEPHENS LC, JIANG GL, ANG KK, PETERS LJ. Radiation myelopathy in primates treated with conventional fractionation. Int J Radiat Oncol Biol Phys 1990; 19: 935-940.
29. JOINER M, BENTZEN SM. Time-dose relationships: the linear-quadratic approach. In: STEEL GG, editor. Basic clinical radiobiology. 3rd edition, London: Arnold. 2002; 120-133.
30. BENTZEN SM, BAUMANN M. The linear-quadratic model in clinical practice. In: STEEL GG, ed. Basic clinical radiobiology. 3rd edition, London: E. Arnold 2002; 134-146.
31. BAUMANN M, SAUNDERS M, JOINER MC. Modified fractionation. In: STEEL GG, ed. Basic clinical radiobiology. 3rd ed., London: E. Arnold 2002; 147-156
32. MUNRO TR, GILBERT CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol 1961; 34: 246-251.
33. BAUMANN M, DUBOIS W, Surr HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990; 123: 325-330.
34. DUBBEN HH, THAMES HD, BECK-BORNHOLDT HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998; 47: 167-174.
35. BENTZEN SM. Dose-response relationships in radiotherapy. In: STEEL GG, ed. Basic clinical radiobiology. 3rd ed., London: E. Arnold. 2002; 94-104.
36. HERRMANN T, BAUMANN M, VOIGTMANN L, KNORR A. Effect of irradiated volume on lung damage in pigs. Radiother Oncol 1997; 44: 35-40.
37. LIAO ZX, TRAVIS EL, TUCKER SL. Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung. Int J Radiat Oncol Biol Phys 1995; 32: 1359-1370.
38. HOPEWELL JW, TROTT KR. Volume effects in radiobiology as applied to radiotherapy. Radiother Oncol 2000; 56: 283-288.
39. BURMAN C, KUTCHER GJ, EMAMI B, GOITEIN M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991; 21: 123-135.
40. STEWART FA, VAN DER KOGEL AJ. Volume effects in normal tissues. In: STEEL GG, editor. Basic clinical radiobiology. 3rd edition, London: Arnold. 2002; 42-51.
41. VAN LUIJK P, BIJL HP, KONINGS AW, VAN DER KOGEL AJ, SCHIPPERS JM. Data on Dose-volume effects in the rat spinal cord do not support existing NTCP models. Int J Radiat Oncol Biol Phys 2005; 61: 892-900.
42. LYMAN J. Complication probability as assessed from dose-volume histograms. Radiat Res 1985; 104: S13-19.
43. EMAMI B, LYMAN J, BROWN A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-122.
44. BOERSMA LJ, VAN DEN BRINK M, BRUCE AM et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83-92.
45. BAUMANN M, BENTZEN SM. Clinical manifestations of normal-tissue damage. In: STEEL GG, editor. Basic Clinical Radiobiology. 3 edition, London: Arnold 2002.
46. BENTZEN SM, VAETH M, PEDERSEN DE, OVERGAARD J. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now! Int J Radiat Oncol Biol Phys 1995; 32: 1531-1534.
47. JUNG H, BECK-BORNHOLDT HP, SVOBODA V, ALBERTI W, HERRMANN T. Quantification of late complications after radiation therapy. Radiother Oncol 2001; 61: 233-246.
48. BENTZEN SM, OVERGAARD J. Patient-to-Patient Variability in the Expression of Radiation-Induced Normal Tissue Injury. Semin Radiat Oncol 1994; 4: 68-80.
49. BAUMANN M. Impact of endogeneous and exogeneous factors on radiation sequelae. In: DUNST J, SAUER R, editor. Late sequelae in oncology. Berlin: Springer 1995; 3-12.
50. SAFWAT A, BENTZEN SM, TURESSON I, HENDRY JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52: 198-204.
51. ANDREASSEN CN, ALSNER J, OVERGAARD J. Does variability in normal tissue reactions after radiotherapy have a genetic basis-where and how to look for it? Radiother Oncol 2002; 64: 131-140.
52. TWARDELLA D, CHANG-CLAUDE J. Studies on radiosensitivity from an epidemiological point of view - overview of methods and results. Radiother Oncol 2002; 62: 249-260.